News
Starting in 2023, a new clinical trial called NAC Attack will be launched to test an oral medication, N-acetylcysteine (NAC), as a potential therapy for patients with retinitis pigmentosa (RP). NAC Attack…
Read More about NAC Attack: A Phase III clinical trial to test an oral therapy for retinitis pigmentosa
Dr. Sachdev Sidhu (University of Toronto) is a biomedical engineer with extensive experience in drug development. Dr. Sidhu established the Toronto Recombinant Antibody Centre (TRAC) which houses a state-of-the-art platform to generate…
Read More about Developing a new therapy for age-related macular degeneration and diabetic retinopathy.
Teamwork really does make the dream work! We are excited to share news of a Fighting Blindness Canada (FBC) funded discovery recently published in the journal Science Advances achieved through a collaboration…
Read More about FBC scientists collaborate to identify new gene for retinitis pigmentosa
Fighting Blindness Canada is pleased to hear the announcement that Canadians are one step closer to accessing Luxturna® (generic name: voretigene neparvovec)i, a sight-saving gene therapy. The pan-Canadian Pharmaceutical Alliance has concluded…
Read More about Fighting Blindness Canada urges Provinces to Sign Agreement for Sight-Saving Treatment
Comic Vision is Fighting Blindness Canada’s (FBC) signature comedy show in support of vision research and has been bringing people together since 1999, spreading hope, vision loss awareness, and education by using…
Read More about Comic Vision is Back Live and In-Person!
Amy Amantea is the host of Accessible Media Inc.’s (AMI), Accessing Art with Amy, where she connects with artists with disabilities across Canada. As an artist impacted by vision loss, Amy is…
Read More about Eliminating Barriers in the Art Space with Amy AmateaJoin the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.
